KURA

ANALYST NOTE: KURA ONCOLOGY, INC. (KURA) Date: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, Kura Oncology presents a confirmed coil setup, indicating a breakout has fired and the structure is actionable. The conservative entry level for this confirmed setup is $12.53. The current price is $11.71, representing an extension of -6.5% relative to the conservative entry. The setup exhibits high structural quality, evidenced by an ATR at breakout of 5.1% and a current ATR of 5.6%, both falling within the high volatility bucket (4–6%) historically associated with strong momentum potential. The presence of the confirmed coil serves as a positive readiness signal, though the current price action suggests a pullback from the initial breakout point rather than a continuation of the immediate surge.

(2) The Thesis Layer The primary secular thesis driving this setup is Biotech & GLP-1 → Oncology, with Kura Oncology positioned as a direct beneficiary with high confidence. The company is not merely a participant but a commercial-stage operator delivering precision medicines specifically for acute myeloid leukemia (AML). The directness of the exposure is anchored in the successful launch of KOMZIFTI (ziftomenib), a first-in-class menin inhibitor. While the company maintains a diversified pipeline, the immediate secular tailwind is the specific demand for targeted therapies in NPM1-mutated AML, a niche where Kura has established a leadership position. The setup is supported by the broader secular trend of shifting oncology treatment from broad cytotoxic chemotherapy to precision molecular targeting.

(3) The Business Kura Oncology operates as a fully-integrated commercial-stage biopharmaceutical company focused on discovering and advancing small-molecule cancer treatments. As of the date of this analysis, the company's business model has transitioned from pure R&D to commercialization, evidenced by the launch of its first product, KOMZIFTI.

• Commercial Launch & Revenue: The company initiated commercial sales of KOMZIFTI on November 21, 2025. In the first full quarter of commercialization (Q1 2026), the company generated $5.8 million in net product revenue, exceeding management expectations. This figure represents 85 new patient starts and nearly 160 total prescriptions across approximately 60 activated accounts.
• Market Access: Management has secured coverage parity or better for more than 93% of covered lives in the United States, with no label restrictions beyond the approved indication.
• Pipeline & Strategy: The company is advancing its lead asset, ziftomenib, into the frontline setting via the KOMET-017 trial. This innovative "one-stop shop" design allows for simultaneous enrollment into two independent Phase III trials (intensive and non-intensive regimens) at each activated site. Management expects topline results for the MRD-negative CR accelerated endpoint in the intensive setting in 2028.
• Financial Runway: As of March 31, 2026, the company's cash position, combined with anticipated payments of $180 million under its collaboration agreement with Kyowa Kirin, is expected to fund the ziftomenib AML program through the first top-line Phase III results.

(4) The Archetype and Conviction Kura Oncology fits the Growth Leader archetype. The company has successfully executed the transition from a clinical-stage biotech to a commercial entity with a revenue-generating asset.

• Valuation & Financials: The financial spine indicates a path to profitability is being funded by current cash and collaboration payments, though the company remains in a loss-making phase with forward consensus EPS of -3.55 for FY1 and -2.66 for FY2. This is typical for a commercial-stage biotech investing heavily in Phase III expansion.
• Conviction Stack:
• Thesis Strength: High. The company is a direct play on a high-conviction secular theme (precision oncology) with a unique mechanism of action (menin inhibition).
• Evidence Quality: Strong. The evidence base includes specific revenue figures ($5.8M Q1), clear market access data (93% coverage), and defined clinical milestones (KOMET-017).
• Structural Quality: High. The ATR metrics (5.1% breakout, 5.6% current) indicate a stock with significant volatility and institutional interest, fitting the "high" bucket for momentum setups.
• Rerating Potential: Significant. The market is currently pricing in the initial commercial success; rerating potential exists as the company moves toward the Phase III data readouts in 2028 and expands into the frontline AML market, which management estimates at a $7.0 billion annual opportunity.

(5) Invalidating Factors, Strengthening Factors, and Gaps

• Strengthening Factors: Continued acceleration in net product revenue (e.g., Q2 2026 results showing growth beyond the 57% Q1-to-Q2 trajectory seen in the news feed), successful enrollment acceleration in KOMET-017, or additional payer coverage expansions.
• Invalidating Factors: A significant slowdown in patient starts, loss of key payer coverage, or a material delay in the KOMET-017 trial enrollment or timeline that jeopardizes the 2028 data readout.
• Gaps in Evidence: While the Q1 2026 revenue is confirmed, the specific Q2 2026 financial results (reported in news dated August 2026) are not yet available as of the June 13, 2026 event date. Therefore, the immediate momentum of the second quarter is not yet quantified in the primary evidence base. Additionally, specific long-term pricing power dynamics beyond the initial 93% coverage are not detailed in the current filings.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Confirmed coil breakout with high ATR structural quality; $5.8M Q1 revenue beat and 93% payer coverage secured; KOMET-017 trial design enables efficient Phase III data generation. Key risks: Cash burn rate relative to revenue growth; potential delays in KOMET-017 enrollment or 2028 data readout; competitive landscape in NPM1-mutated AML. Rating boundary: The rating is a Buy rather than a Strong Buy because the current price is 6.5% below the conservative entry, indicating a pullback that requires confirmation of support before aggressive scaling. It is not a Speculative rating because the company has moved beyond the R&D phase into commercialization with verified revenue and a clear funding runway. Sizing hint: Position size should reflect the high ATR volatility; consider scaling in on a retest of the breakout zone rather than chasing the current pullback. Expected path: Management expects revenue to grow as patient starts increase and the KOMET-017 trial progresses toward 2028 data readouts, with the collaboration payments providing a stable cash floor. Expected horizon: 12 to 24 months for the next major catalyst (KOMET-017 enrollment updates or Q2/Q3 revenue acceleration). Failure mode to watch: A significant miss in the next quarterly revenue report or a material delay in the KOMET-017 trial timeline.